Fc fragment of human immunoglobulin G1 (1-227) [Homo sapiens IGHG1*03 (hinge (1-10), CH2 L<sup>14</sup>>A, L<sup>15</sup> >A (11-120), CH3 (121-226), CHS (226-227))] fused via peptide linker <sup>228</sup>GS<sup>229</sup> to human fibroblast growth factor 21 (FGF-21) fragment 33-209 [Q<sup>55</sup> >C<sup>252</sup>, R<sup>105</sup> >K<sup>302</sup>, G<sup>148</sup> >C<sup>345</sup>, K<sup>150</sup> >R<sup>347</sup>, P<sup>158</sup> >S<sup>355</sup>, S<sup>195</sup> >A<sup>392</sup>, P<sup>199</sup> >G<sup>396</sup>, G<sup>202</sup> >A<sup>399</sup>]-variant (230-406 in the current sequence); dimer (6-6', 9-9')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa
Obesity
Novartis Pharmaceuticalsprotein_peptidePhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 59/ 100
Competitive context
575 Active assets in the Obesity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
vi-0521 VIVUS LLC | Phase 4 | BBB |
Tirzepatide LABORATORIOS INDUFAR | Phase 4 | BBB |
Efsubaglutide Alfa The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 4 | BBB |
Phentermine Russell McCulloh, MD | Phase 4 | BBB |
Deoxycholic Acid University of California, San Diego | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →